Combining the strength of genomics, nanoparticle technology, and direct intraductal delivery for breast cancer treatment

Wei W. Teo, Saraswati Sukumar

Research output: Contribution to journalArticle

Abstract

A large number of genes are altered in cancer cells. Often, reversal or inhibition of just one of these alterations leads to death of the cancer cells. Technological advances in multiple areas are necessary to potentiate clinical translation of these findings. In a recent article, Brock and colleagues reported that overexpressed HOXA1 is a critical event in tumor progression in a mouse mammary tumor model. They developed HOXA1-small interfering RNA nanoparticles and achieved effective therapeutic doses by delivering them intraductally through the nipple to the site of the tumor and at the same time circumvented the systemic immune response. This study strengthens the concept of targeting overexpressed genes by using small interfering RNA and bypassing systemic immunity through local intraductal delivery.

Original languageEnglish (US)
Article number306
JournalBreast Cancer Research
Volume16
Issue number2
DOIs
StatePublished - May 17 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combining the strength of genomics, nanoparticle technology, and direct intraductal delivery for breast cancer treatment'. Together they form a unique fingerprint.

  • Cite this